Di Molfetta Sergio, Feola Tiziana, Fanciulli Giuseppe, Florio Tullio, Colao Annamaria, Faggiano Antongiulio
Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, 70124 Bari, Italy.
Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
J Clin Med. 2022 Feb 16;11(4):1019. doi: 10.3390/jcm11041019.
Lung carcinoids are well-differentiated and low-/intermediate-grade neuroendocrine neoplasms of the lung. Given their relative rarity, and the paucity of data available from prospective studies, no global consensus exists on the systemic treatment of these tumours. In recent years, immune checkpoint inhibitors have revolutionized cancer management and are under evaluation in patients with diverse types of neuroendocrine neoplasms. The aim of this narrative review is to analyse all available data for the use of approved immune checkpoint inhibitors in patients with lung carcinoids. We performed an extensive search for relevant data sources and found five published articles, one meeting abstract, and nine registered clinical trials indicating a growing interest of researchers in this field, and providing preliminary evidence of efficacy for combined nivolumab plus ipilimumab and durvalumab plus tremelimumab regimens in the treatment of advanced and/or metastatic lung carcinoids.
肺类癌是肺的高分化、低/中级别神经内分泌肿瘤。鉴于其相对罕见，且前瞻性研究的数据有限，对于这些肿瘤的全身治疗尚无全球共识。近年来，免疫检查点抑制剂彻底改变了癌症治疗模式，目前正在对多种类型神经内分泌肿瘤患者进行评估。本叙述性综述的目的是分析已批准的免疫检查点抑制剂用于肺类癌患者的所有可用数据。我们广泛搜索了相关数据源，发现了五篇已发表的文章、一篇会议摘要和九项注册临床试验，这表明该领域的研究人员兴趣日益浓厚，并为纳武利尤单抗联合伊匹木单抗以及度伐利尤单抗联合曲美木单抗方案治疗晚期和/或转移性肺类癌的疗效提供了初步证据。
